Does Rallies show Form 4 insider transactions for ERNA?

Yes. Rallies tracks ERNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ERNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ERNA. It does not provide personalized investment advice.

ERNA (Ernexa Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Ernexa Therapeutics Inc. Common Stock (ERNA) is a publicly traded Healthcare sector company. As of May 20, 2026, ERNA trades at $11.24 with a market cap of $14.29M and a P/E ratio of -4.92. ERNA moved +0.00% today. Year to date, ERNA is -60.52%; over the trailing twelve months it is -86.72%. Its 52-week range spans $3.18 to $558.75. Analyst consensus is buy with an average price target of $30.00. Rallies surfaces ERNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ERNA stock inside the company?

Recent ERNA insider activity includes Cherington Charles bought 4.00M, Cherington Charles bought 21.24M, Cherington Charles bought 3.77M, Cherington Charles bought 261.76K, and Singer Nicholas Jason bought 70.82K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ERNA Key Metrics

Key financial metrics for ERNA
Metric	Value
Price	$11.24
Market Cap	$14.29M
P/E Ratio	-4.92
EPS	$-2.24
Dividend Yield	0.00%
52-Week High	$558.75
52-Week Low	$3.18
Volume	51.55K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-14.08M
Gross Margin	0.00%

Recent ERNA Insider Trades

Cherington Charles bought 4.00M (~$2.00M) on Feb 10, 2026.
Cherington Charles bought 21.24M (~$2.22M) on Jun 9, 2025.
Cherington Charles bought 3.77M (~$394.17K) on Apr 2, 2025.
Cherington Charles bought 261.76K (~$858.56K) on Dec 2, 2022.
Singer Nicholas Jason bought 70.82K (~$232.30K) on Dec 2, 2022.

Latest ERNA News

Ernexa’s ERNA-101 Achieves 100% Tumor Elimination in Preclinical Ovarian Models — May 20, 2026
Ernexa Showcases ERNA-101 in KOL Segment and Highlights 100% Survival Preclinical Data — May 11, 2026
Ernexa Therapeutics Plans 1-for-25 Reverse Stock Split to Meet Nasdaq’s $1.00 Rule — Apr 30, 2026
Ernexa Advances ERNA-101 Toward Q3 2026 IND, Backed by $10.5 M Financing — Mar 31, 2026
Ernexa Therapeutics Raises $10.5M via 21M-Share, $0.50 Offering with $0.68 Warrants — Feb 6, 2026

ERNA Analyst Consensus

1 analysts cover ERNA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.00.

Common questions about ERNA

Who is trading ERNA stock inside the company?: Recent ERNA insider activity includes Cherington Charles bought 4.00M, Cherington Charles bought 21.24M, Cherington Charles bought 3.77M, Cherington Charles bought 261.76K, and Singer Nicholas Jason bought 70.82K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ERNA?: Yes. Rallies tracks ERNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ERNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ERNA. It does not provide personalized investment advice.